Orion Genomics Non-exclusively Licenses MethylScreen™ Technlogy to Qiagen to Market Epigentic Kits to the Research Use Field
Orion Genomics Appoints Steven W. Smith as Vice President of Bioinformatics
Orion Genomics Secures Patents for Proprietary MethylScreen Technology
Potential Diagnostic Test Based on Novel Epigenetic Biomarker Awarded US Patent
Orion and the Malaysian Palm Oil Board co-lead consortium to sequence genome of three oil palm varieties and form epigenetics collaboration
Orion Genomics and Novartis Enter Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement with Johns Hopkins University
Orion Genomics discovers and validates novel breast cancer biomarkers, including the most frequent DNA alterations detected in breast cancer to date; publishes results in PLoS ONE.
Orion Genomics announces the discovery and validation of biomarkers for lung and ovarian cancer; presents results at the 2007 Annual Meeting of the American Association for Cancer Research in Los Angeles, California
Orion Genomics announces the issuance of US Patent No. 7,186,512, covering MethylScope Technology, a best in class genome-wide novel biomarker discovery platform
Orion Genomics announces the validation of MethylScope Technology and the discovery of biomarkers for brain cancer in a genome-wide methylation study published in Carcinogenesis
Orion Genomics announces the validation of novel breast cancer biomarkers
Orion Genomics forms collaboration with the Mayo Clinic to study the clinical Utility of Orion's breast cancer screening tests
Researchers at Orion Genomics and University of Glasgow collaborate to identify epigenetic biomarkers for early cancer diagnosis and personalized therapy selection
Researchers at Orion Genomics and Washington University in St. Louis collaborate to develop new cancer tests
Orion Genomics and Andrew Feinberg, M.D. collaborate to explore the role of DNA's "Second Code" in colon cancer
Orion Genomics and NCSU awarded $1.59 Million NSF Grant to determine sequence of parasitic worm
Orion Genomics named a Top 50 Company by Deloitte & Touche and the St. Louis RCGA
Orion Genomics and North Carolina State University Extend Tobacco Genome Initiative
ViaLactia, Orion Genomics provide proprietary ryegrass sequence data to Cold Spring Harbor Laboratory to enable annotation of public plant sequences
Orion Genomics President/Chief Executive awarded as a member of "40 Under 40" by the St. Louis Business Journal
For press releases or for media inquiries, please contact:
Canale Communications for Orion Genomics
Carolyn Hawley
619-849-5375